Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 6415 results found. Search for [ Japan ]

Results 40 to 60 of 6415
Nirbhay Kumar
June 25, 2020
For fresh investment, Odisha has charted out plans and identified various sectors such as metal and mining in which it has inherent strength. The state is targetting specific types of companies for investment


Reuters
June 25, 2020
Cipla and Hetero are among a bevy of drugmakers which have licensing agreements with US-based Gilead Sciences Inc, the original manufacturer of remdesivir, to make and sell the drug in 127 low- and middle-income countries


BusinessToday.In
New Delhi, June 24, 2020
The global average of online video viewing has jumped four times to four hours and 3 minutes per day from a single hour average measured in the State of Online Video 2019 study just six months ago


Rashmi Pratap
New Delhi, June 24, 2020
Why the sharp recovery and sustained run in stock markets is built on weak fundamentals. Despite the fall, they are trading at double the valuation of the 2008 Lehman crash


Manu Kaushik
June 24, 2020
As per Cyfirma, a cyber threat intelligence firm, the conversation in the dark web expressing interest to hack Indian assets has increased substantially, and attacks are nearly up 200 per cent since the beginning of June


BusinessToday.In
New Delhi, June 23, 2020
Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report


Chitranjan Kumar
New Delhi, June 23, 2020
Mukesh Ambani improved his position by one slot to become 8th richest person in the world with a net worth of $66 billion


Reuters
June 23, 2020
Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees


BusinessToday.In
New Delhi, June 23, 2020
The 2011 round of World Bank's International Comparison Program (ICP) had ranked India ahead of Japan and after the US and China


Shubham Verma
New Delhi, June 23, 2020
The Reno 3A comes with a set of four cameras at the back, which is very much like what we have seen on the Reno 3 5G.


Manu Kaushik
June 23, 2020
Hackers particularly targeted three central government ministries - Ministry of Foreign Affairs, Ministry of Defence, and Ministry of Information and Broadcasting


Reuters
June 23, 2020
Indian drugmakers Hetero Labs and Cipla Ltd on Sunday gained approval to begin selling their generic versions of remdesivir in the country


Reuters
June 22, 2020
Italy, Japan and Britain are expected to suffer the biggest debt increases at around 25 percentage points of their respective GDPs, while the United States, France, Spain, Canada and New Zealand will all see theirs jump roughly 20 ppts


Reuters
June 22, 2020
The proposed easing of restrictions will be put to the government's coronavirus task force on Friday


PB Jayakumar
June 22, 2020
Pharma major is hopeful of exporting Fabiflu after the study proves efficacy of the drug in coronavirus treatment


Reuters
June 22, 2020
Highlighting economic challenges from the impact of social restrictions to contain the pandemic, Apple Inc said on Friday it would temporarily shut 11 U.S. stores as coronavirus cases rise in some states, triggering selling in stocks


Nevin John
New Delhi, June 21, 2020
Tata Motors' auto division in India has reportedly dropped its capital expenditure by almost 56 percent to Rs 1,500 crore for the current year


BusinessToday.In
New Delhi, June 21, 2020
These two companies have been approved at a time when coronavirus cases in India are spiralling like never before and putting tremendous pressure on our healthcare system


PB Jayakumar
New Delhi, June 20, 2020
Glenmark developed active pharmaceutical ingredient and formulation for FabiFlu through in-house R&D; DCGI allowed fasttrack trials with Phase III in limited patients; approval process is also under Emergency Use Authorisation


BusinessToday.In
New Delhi, June 20, 2020
Company says Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19; can offer a rapid reduction in viral load in four days and provide faster symptomatic and radiological improvement


PAGES 3 OF 321  12345